RxSight, Inc. (NASDAQ:RXST – Get Free Report) Director Bakker Juliet Tammenoms sold 18,484 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $30.06, for a total value of $555,629.04. Following the transaction, the director now owns 83,062 shares of the company’s stock, valued at approximately $2,496,843.72. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
RxSight Price Performance
Shares of RXST stock traded up $0.40 during midday trading on Friday, reaching $29.97. 307,790 shares of the company were exchanged, compared to its average volume of 318,061. The company’s 50 day moving average price is $29.27 and its two-hundred day moving average price is $21.83. The company has a market cap of $1.07 billion, a P/E ratio of -14.86 and a beta of 0.66. RxSight, Inc. has a 12 month low of $9.78 and a 12 month high of $33.77. The company has a debt-to-equity ratio of 0.12, a quick ratio of 9.81 and a current ratio of 10.89.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. Oppenheimer raised their target price on RxSight from $29.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, August 8th. Wells Fargo & Company lifted their price objective on shares of RxSight from $17.00 to $27.00 in a research report on Monday, June 5th. Needham & Company LLC restated a “buy” rating and issued a $34.00 target price on shares of RxSight in a research report on Tuesday, August 8th. BTIG Research lifted their price target on RxSight from $29.00 to $36.00 in a report on Monday, July 17th. Finally, Bank of America increased their price objective on RxSight from $24.00 to $32.00 in a report on Friday, July 7th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.50.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. raised its position in RxSight by 39.2% in the first quarter. Ameritas Investment Partners Inc. now owns 1,907 shares of the company’s stock worth $32,000 after acquiring an additional 537 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of RxSight in the 2nd quarter worth approximately $70,000. IFP Advisors Inc bought a new stake in shares of RxSight in the 2nd quarter worth approximately $62,000. FNY Investment Advisers LLC acquired a new stake in RxSight during the second quarter valued at approximately $126,000. Finally, Counterpoint Mutual Funds LLC bought a new stake in RxSight during the second quarter worth approximately $131,000. Institutional investors and hedge funds own 53.61% of the company’s stock.
RxSight Company Profile
RxSight, Inc, an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.